Fund+ provides smart (equity) money for:
- active in life sciences (primary focus on therapeutics, not excluding diagnostics and medical devices), with a strong patient-centric approach addressing unmet medical needs
- in an advanced development stage (first round and subsequent financing)
- with an experienced management team respecting highest ethical values
- presenting a solid business plan
Fund+ wants to become a significant minority shareholder (10 -20%) and can rely on a wide international network of partners that could co-invest. The intended investment size per project will be between EUR 3 million and EUR 10 million.
Fund+ wants to become a long term partner of companies, create value for its shareholders as well generate a tangible beneficial societal impact.
The societal impact will be evaluated by using a proprietary SRI scorecard that is based on the SRI policy that you can find here.